Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

6.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.4K
Clinical Trials01:16

Clinical Trials

11.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

281
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
281
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

379
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
379
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

202
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
202

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Making in silico predictive models for toxicology FAIR.

Regulatory toxicology and pharmacology : RTP·2023
Same author

Statistical analysis of preclinical inter-species concordance of histopathological findings in the eTOX database.

Regulatory toxicology and pharmacology : RTP·2022
Same author

Retrospective analysis of the potential use of virtual control groups in preclinical toxicity assessment using the eTOX database.

Regulatory toxicology and pharmacology : RTP·2022
Same author

In silico tools for sharing data and knowledge on toxicity and metabolism: derek for windows, meteor, and vitic.

Toxicology mechanisms and methods·2009
Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026
Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
Same journal

Targeting the GLP-1 receptor pathways for dual management of obesity and depression.

Drug discovery today·2026
Same journal

Chemical intervention strategies targeting MYC for cancer therapy.

Drug discovery today·2026
Same journal

How many protein pairs can we chemically target?

Drug discovery today·2026
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Is preclinical data sharing the new norm?

Katharine A Briggs1

  • 1Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds LS11 5PS, UK.

Drug Discovery Today
|May 14, 2016
PubMed
Summary
This summary is machine-generated.

Preclinical data sharing is increasing but not yet standard. Sharing proprietary preclinical data offers benefits but faces barriers. Developing standard operating procedures can maximize advantages and minimize risks.

More Related Videos

Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

7.0K
Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

871

Related Experiment Videos

Last Updated: Mar 21, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

7.0K
Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

871

Area of Science:

  • Biomedical Research
  • Drug Discovery
  • Data Science

Background:

  • Preclinical data sharing is becoming more frequent.
  • It is not yet a standard practice in the scientific community.
  • Currently, data sharing is often limited to specific research projects.

Purpose of the Study:

  • To discuss the advantages of sharing proprietary preclinical data.
  • To identify the primary obstacles hindering data sharing.
  • To propose solutions for overcoming these barriers and promoting data sharing.

Main Methods:

  • Review of successful preclinical data sharing initiatives.
  • Analysis of common barriers encountered in data sharing.
  • Development of recommendations for establishing data sharing protocols.

Main Results:

  • Successful initiatives demonstrate the value of data sharing.
  • Key barriers include concerns about intellectual property, data quality, and lack of infrastructure.
  • Overcoming barriers requires clear guidelines, standardized formats, and secure platforms.

Conclusions:

  • Preclinical data sharing offers significant benefits for research acceleration and innovation.
  • Establishing standard operating procedures is crucial for maximizing benefits and mitigating risks.
  • Widespread adoption of data sharing practices will advance scientific discovery.